Molenaar, R., Radivoyevitch, T., Nagata, Y., Khurshed, M., Przychodzen, B., Makishima, H., … Maciejewski, J. (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2796 (Original work published 2018)

Molenaar, R., Maciejewski, J., Wilmink, J., & Van Noorden, C. (2018). Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. https://doi.org/10.1038/s41388-017-0077-z (Original work published 2018)